The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
Top Cited Papers
Open Access
- 3 May 2005
- journal article
- guideline
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 92 (9), 1599-1610
- https://doi.org/10.1038/sj.bjc.6602550
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weightsJournal of Magnetic Resonance Imaging, 2004
- Measuring blood volume and vascular transfer constant from dynamic, T‐weighted contrast‐enhanced MRIMagnetic Resonance in Medicine, 2004
- DCE-MRI in clinical trials: data acquisition techniques and analysis methodsInternational journal of clinical pharmacology and therapeutics, 2003
- Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance ImagingJournal of Clinical Oncology, 2003
- Structural, Functional, and Molecular MR Imaging of the MicrovasculatureAnnual Review of Biomedical Engineering, 2003
- Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UKBritish Journal of Cancer, 2003
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- A model of the dual effect of gadopentetate dimeglumine on dynamic brain MR imagesJournal of Magnetic Resonance Imaging, 1999
- Contrast agents in functional MR imagingJournal of Magnetic Resonance Imaging, 1997
- Comparative signal intensity measurements in dynamic gadolinium‐enhanced MR mammographyJournal of Magnetic Resonance Imaging, 1994